from individual potential to the strength of an alliance of territories

There is currently no doubt that personalized medicine is one of those health-related sectors in which: technology, research and innovation will play a more important role.

There is no region that does not work in a more or less sophisticated way to equip its health system – whose management is devolved to the regional governments – with all reeds needed to make this sector a reference in the medium and long term.

Anyway, not all autonomy follows the same strategy. There are two speeds: that of those who have been a reference for some time, who choose to keep this collaborative but individual work, and that of those regions that want to potentially gain by forging alliances.

[La plataforma de fabricación celular que lleva a Asturias a un nuevo nivel en el sector de la medicina personalizada]

In the first group we naturally find Navarre. The internationally recognized genomic technology or the opening of the Massive Sequencing Center in the Foral community -the second state-owned company in all of Spain- These are sufficient reasons to take into account the work that the region has developed in this sector.

There are other regions that, while not characterized by their prominence in personalized medicine, have boosted their strategies individually. It is the case of Asturiaswhich, as D+I explained a few days ago, has formalized the purchase of a cell production platform that will enable research and development of its own and personalized medicines.

The fact that these regions work individually Of course, it doesn’t mean they don’t have open lines of cooperation with othersother territories.

What happens – and therein lies the difference – is that: other autonomous communities, with the support of the central government, have decided to join forces.

[Tecnología genómica y enfermedades raras: Navarra se vende en Brasil como líder en medicina personalizada]

This week has been presented in Castilla-La Mancha a research project on biotechnology applied to healthin which seven regions participate, including Castilian-La Mancha and Andalusia, Aragon, Catalonia, Extremadura, Basque Country and Galicia.

This is a unique research project that will help create a nationwide network of personalized medicine.

This project, which has the title of ‘Development of tools for diagnosis, prognosis and advanced or targeted therapies in personalized medicine’ It is coordinated by the Ministry of Science and Innovation and is part of the Complementary Plans charged to the funds of the Recovery, Transformation and Resilience Plan.

The Minister of Education, Culture and Sports, Rosa Ana Rodríguez, has emphasized that thanks to this initiative she several research programs “which aim to find scientific solutions to improve treatments and the quality of life of patients with serious diseases”.

Supercomputing, robotics or nanotechnology

For example, it specified that “through this project” a large national network in personalized medicine is being created allowing the treatment of some serious diseases to be adapted to the specificities of each patient, achieving a more effective treatment with fewer side effects. And Castilla-La Mancha will lead projects in this network thanks to this initiative.”

Before, Elements such as biomedicine, artificial intelligence, supercomputing, robotics, sensors and nanotechnology are combined designing and manufacturing new diagnostic, prognostic and therapeutic systems and devices.

“The goal is that within two or three years we will have a range of drugs that can help with these treatments,” the aid worker assured.

The project embraces the importance of “institutional cooperation” and research groups belonging to UCLM participate, such as the Associated Neurodeath Unit, Computer Engineering, Faculty of Medicine of Albacete and Faculty of Environmental Sciences and Biochemistry, and SESCAM, University Hospital of Albacete and University Hospital of Toledo.

Castilla-La Mancha also provides patient cohorts (patient groups that are part of a clinical trial) in two major pathologies: one with persistent COVID and the other with non-alcoholic fatty liver disease. The possible inclusion of additional cohorts is planned.

The project has six action lines: BERM platform (microscopy); Implementation and analysis of databases in precision medicine; Drug screening platform and drug interaction analysis; Development of biological disease models; Development of nanopharmaceuticals (coordinated by Castilla-La Mancha) and advanced therapies and medical robotics. The research groups of Castilla-la Mancha participate in all action lines.

Leave a Comment